Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7021 to 7035 of 7679 results

  1. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued [GID-TA10527]

    Technology appraisal guidance
    Discontinued

  2. Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]

    Discontinued [GID-TA10531]

    Technology appraisal guidance
    Discontinued

  3. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    In development [GID-TA10597] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    In development [GID-TA10958] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    In development [GID-TA10583] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued [GID-TA10739]

    Technology appraisal guidance
    Discontinued

  7. Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]

    Discontinued [GID-TA10382]

    Technology appraisal guidance
    Discontinued

  8. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued [GID-TAG332]

    Technology appraisal guidance
    Discontinued

  9. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued [GID-TAG418]

    Technology appraisal guidance
    Discontinued

  10. Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

    Discontinued [GID-TA10337]

    Technology appraisal guidance
    Discontinued

  11. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued [GID-TA10236]

    Technology appraisal guidance
    Discontinued

  12. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued [GID-TAG397]

    Technology appraisal guidance
    Discontinued

  13. Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

    Discontinued [GID-TA10159]

    Technology appraisal guidance
    Discontinued

  14. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued [GID-TA10803]

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

    Discontinued [GID-TA10380]

    Technology appraisal guidance
    Discontinued